Pregnancy Clinical Trial
Official title:
SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit
Verified date | December 2017 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary Aim: To test the efficacy of a SMS text-based scheduled gradual reduction (SGR) and
counseling intervention to promote smoking cessation in the late third trimester.
Hypothesis: The rate of smoking cessation in the late third trimester among women in the SGR
Support Messages arm will be higher than among women in the Support Messages arm.
Secondary Aim 1: To assess the effect of the SGR intervention on biochemically validated
prolonged abstinence and smoking reduction during pregnancy.
Secondary Aim 2: To assess the effect of the SGR intervention on smoking abstinence at three
months postpartum.
Secondary Aim 3: To assess the effect of the SGR intervention on the rate of preterm birth.
Status | Completed |
Enrollment | 331 |
Est. completion date | February 20, 2018 |
Est. primary completion date | December 13, 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Women who: - are between 10 and 28 weeks pregnant, - have smoked at least 100 cigarettes in their lifetime, - smoke 3 or more cigarettes per day in the prior 7 days, - are current smokers, - are willing to try to quit smoking, - are enrolled in prenatal care at the clinics from which the study team is recruiting and plan to receive care there throughout their pregnancy, - are age 18 or older, - speak English Exclusion Criteria: - evidence of unstable cognitive or mental health problems who cannot properly provide consent. |
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | biochemically validated seven-day point prevalence smoking abstinence | late third trimester (35 weeks) | ||
Secondary | prolonged smoking abstinence | late third trimester (35 weeks gestation) | ||
Secondary | biochemically validated smoking reduction | late third trimester (35 weeks gestation) | ||
Secondary | biochemically validated postpartum smoking abstinence | 3 months postpartum | ||
Secondary | preterm birth | delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Completed |
NCT02520687 -
Effects of Dietary Nitrate in Hypertensive Pregnant Women
|
Phase 1 |